HMBD-002 is under clinical development by Hummingbird Bioscience and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HMBD-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HMBD-002 overview

HMBD-002 is under development for the treatment of solid cancers such as liver cancer (hepatocellular carcinoma), colon cancer, triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and hematological cancers. The therapeutic candidate is a monoclonal antibody. It is developed based on ONTarget, mAbPredict, mAbHits and mAbAdvance technologies. It acts by targeting V-domain immunoglobulin (Ig)-containing suppressor of T-cell activation (VISTA). It is administered through intravenous route.

Hummingbird Bioscience overview

Hummingbird Bioscience (Hummingbird) is a biotechnology company that discover and develops drugs to treat cancer, autoimmune diseases and infectious disorders. The company is investigating HMBD-001, an anti-HER3 neutralizing antibody to treat solid tumors; HMBD-002, an anti-vista neutralizing antibody for the treatment of cancer; and HMBD-004 for multiple myeloma. It is also evaluating COVID-19 mAb, a SARS-CoV-2 neutralizing antibody for the treatment of SARS-CoV-2 virus. Hummingbird employs its proprietary mAbPredict platform to provide rational antibody discovery that enables targeted identification and isolation of antibodies on a target protein and mAbHits platform that controls the immune system response to optimize the production of a higher number of antibodies against the desired epitopes. The company has operations in the US and Singapore. Hummingbird is headquartered in Singapore.

For a complete picture of HMBD-002’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.